Article
Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels
Registro en:
SALLES, F. et al. Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels. Transactions of The Royal Society of Tropical Medicine and Hygiene, v. 107, p. 526–529, 2013.
0035-9203
10.1093/trstmh/trt052
Autor
Salles, Fernanda
Bacellar, Andrea
Amorim, Mirla
Orge, Glória
Sundberg, Michael
Lima, Márcia
Santos, Silvane
Porto, Aurélia
Carvalho Filho, Edgar Marcelino
Resumen
Carvalho Filho, Edgar Marcelino de. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”. NIH Grants AI-079238, and the Brazilian National Research Council (CNPq); Fundação de Amparo a
Pesquisa do Estado da Bahia. EC is a senior investigator with CNPq. Human T cell lymphotropic virus type 1 (HTLV-1) infection has been associated with recurrent and disseminated strongyloidiasis and adult T cell leukemia/lymphoma (ATLL). Methods:We compared immunological aspects and markers for ATLL in HTLV-1 patients with or without strongyloidiasis,
and evaluated the influence of Strongyloides stercoralis treatment on the immune response and clinical
outcomes of HTLV-1 infection.
Results: Levels of TNFa and IFNg were lower in patients coinfected with HTLV-1 and S. stercoralis than in patients
with HTLV-1 only (p , 0.05), and there was an increase in TNFa levels after anthelmintic treatment. Levels
of sIL-2R were higher in patients with HTLV-1 coinfected with S. stercoralis and anthelmintic treatment decreased
sIL-2R levels (p,0.05). The one patient who developed ATLLwas coinfected with S. stercoralis.
Conclusion: These data showthat helminthic infection has a modulatory role inHTLV-1 infection and that S. stercoralis
may be a cofactor in the development ofATLL.